Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Reconciling Reconciliation Tax Bills

    In this Economics Weekly, Richard de Chazal discusses the One Big Beautiful Bill Act, highlighting some of the main areas where it supports growth and where it will detract from it, as well as section 899.

    Read more

  • Monthly Macro: Tariffs, Tensions, and Turning Points

    William Blair macro analyst Richard de Chazal unpacks the latest on global tariffs, inflation pressures, recession risks, and why smidcap stocks might be poised for a comeback in a shifting economic landscape.

    Listen to the podcast

  • Brightflag Has Agreed to Be Acquired by Wolters Kluwer

    William Blair acted as exclusive financial advisor to Brightflag, a portfolio company of One Peak Partners, Sands Capital, Frontline Ventures, Tribal Ventures, and Enterprise Ireland, in connection with its pending sale to Wolters Kluwer (EURONEXT: WKL) for €425 million.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures